FGF21 gene therapy as treatment for obesity and insulin resistanceEMBO MOLECULAR MEDICINEIF8.32018-07-09189OAAI
Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIIDHUMAN MOLECULAR GENETICSIF3.22017-02-1745OAAI
Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIICDISEASE MODELS & MECHANISMSIF3.32016-09-0120OAAI
CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)JCI INSIGHTIF6.12016-06-1672OA
Correction of CNS and Somatic Pathology by Intra-Cerebrospinal Fluid Gene Therapy for Mucopolysaccharidosis Type IIMOLECULAR THERAPYIF122016-05-010OAAI
Biochemical, histological and functional correction of mucopolysaccharidosis Type IIIB by intra-cerebrospinal fluid gene therapyHUMAN MOLECULAR GENETICSIF3.22014-12-1854OAAI
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyJOURNAL OF CLINICAL INVESTIGATIONIF13.62013-07-01199OA
Insulin-like Growth Factor I (IGF-I)-induced Chronic Gliosis and Retinal Stress Lead to Neurodegeneration in a Mouse Model of RetinopathyJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92013-06-0123OAAI